Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- NEW PRODUCTS
June 12, 2006
- Nichi-iko Revises Its Business Forecast Upward
June 12, 2006
- MEDICAL DEVICE NEWS IN BRIEF
June 12, 2006
- Novartis' Smoking Cessation
June 12, 2006
- 52 Companies Utilized Contract Training for MRs in FY2005: MREAC
June 12, 2006
- SURVEY an article
June 12, 2006
- JAPIC Regulatory Affairs Seminar
June 12, 2006
- OPINION
June 12, 2006
- NHO to Cut Number of Drugs
June 12, 2006
- Wakomoto Resumes GE Drug Development in Field of Ophthalmology
June 12, 2006
- SELF-MEDICATION NEWS IN BRIEF
June 12, 2006
- Pfizer Japan Aims for Top
June 12, 2006
- Korosho to Prepare New Treatment GL for MS
June 12, 2006
- Social Security Benefits of \141 Tril.
June 12, 2006
- Pfizer Japan Will Meet Cost-cutting
June 12, 2006
- REGULATORY NEWS IN BRIEF
June 12, 2006
- We Need to Improve Infrastructure for Drug Discovery: Mr Morita of FPMAJ
June 12, 2006
- Yoh Narimatsu Now Steering
June 12, 2006
- Simultaneous Global
June 12, 2006
- Wakunaga Licenses New Quinolone to Rib-X
June 12, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…